upgrad buy lessen gener
upgrad buy improv setup
upgrad buy abat concern around us gener neg
impact remedi larg us manufactur facil look benign industry-level
gener price show sign stabil improv new product launch outlook
mix ex-fx intern segment perform well improv segment
profit margin updat reflect success integr meda acquisit
undemand valuat after-market share trade impli
ev/ebitda multipl versu peer group averag
trim po reflect rebas epipen g-copaxon
maintain multipl ebitda view stock pullback attract
remedi mfg qualiti issu larg morgantown facil impact
myl busi look manag one myl top ten gross margin product
made facil evid myl gross margin outpac
our/street est bp respect multipl quarter true y/i
perform sinc integr meda acquisit see encourag constant
currenc growth myl key intern market overal segment profit margin
eu row risen past quarter chart tabl taken togeth
exit much encourag myl base busi outlook
takeaway us advair gener file mgmt comment indic compani
receiv complet respons letter applic compani expect
approv soon prior mid-octob fda action date management note
fda final stage label review size advair brand
shrunk significantli past year remain net sale near-
term approv may confer lead market vs closest gener competitor
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
global pharmaceut compani
develop manufactur market
pharmaceut product span three segment
gener over-the-count brand specialti
product north american biggest market
account approxim total
sale follow europ
remaind rest world becom
one largest specialti gener player
combin organ growth
number signific acquisit
rate buy abat concern around
us gener industry-level gener price
show sign stabil improv new
integr undemand valuat
share trade impli ev/ebitda
multipl versu peer group averag
biosimilar neulasta fulphila share pre-fil syring segment
market make prescript accord neulasta
brand sale would expect along recent approv
enjoy earli mover advantag forecast sale
chart yoy growth report segment profit
note consensu estim came first order analyt unless note otherwis bloomberg
tabl y/i growth ex-u net sale constant currenc
exhibit confirm guidanc
number share
updat
updat
updat
updat
updat
updat
updat
updat
price object po base multipl ebitda
rel gener peer believ share trade similar
multipl gener peer lower closest peer teva consensu
latter benefit low trough year uptick clinic
de-risk spec brand furthermor less visibl
earn profil view compani gener growth driver less durabl sourc
growth teva key spec brand believ dcf appropri
valuat methodolog littl visibl outlook beyond
one two year multipl take follow consider launch
g-advair gener advair relat conting payment mid-single-digit
growth eu row busi
risk po approv g-advair greater-than-expect competit
pressur copaxon gener
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
